The state of California promotes programs for self-production of insulin. The governor of California, Gavin Newsom, allocated one hundred million dollars from the new state budget for this purpose. The governor is known for his position, ever since his election in 2019, which supports the self-production of generic drugs
[Translation by Dr. Moshe Nachmani]
The state of California promotes programs for self-production of insulin. The governor of California, Gavin Newsom, allocated one hundred million dollars from the new state budget for this purpose. The governor is known for his position, ever since his election in 2019, that supports the self-production of generic drugs.
The plan is based on an executive order Newsom signed when he was elected in 2019, an order aimed at putting California on a path to self-manufacturing prescription drugs. Half of the funding will be used to develop cheap insulin products, and the other half to build production facilities that will strengthen the local supply chain while creating more jobs in the country.
"Nothing epitomizes market failure more than the price of insulin," the governor said on Twitter on July 300. Many Americans pay $500 to $2018 out of pocket each month for this life-saving drug, the governor noted. This is not the only step for self-production of medicines in the different states of the USA. In 30, a group of health care providers launched a non-profit pharmaceutical company in Utah to produce generic (copycat) versions of important and expensive drugs that are in short supply in the US. This company (Civica Rx) currently markets generic drugs, produced by independent contractors, at prices significantly lower than the average market prices. In March, the company announced its plans to produce and market generic versions of three types of insulin - glargine, lispro and aspart. The company will develop and manufacture these products, complete clinical trials on them and submit the required documents to obtain sales approval from the American Food and Drug Administration (FDA). From the moment of receiving this approval, the company plans to sell these versions at a price significantly lower than the market price, a price not to exceed 55 dollars per vial and a price not to exceed XNUMX dollars for a box of five injection pens.
In the past, it was reported that the governor was considering joining this company in order to produce generic versions of essential drugs in California. It is not yet clear whether the company is involved in the governor's new plans.
